Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South Korea’s National Health Insurance Service (NHIS) has included its drug Xpovio (selinexor) in the medical insurance reimbursement drug list, effective from July 1, 2024. The drug is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM).
Xpovio, discovered by U.S.-based Karyopharm Therapeutics Inc. (Nasdaq: KPTI), is the world’s first and only FDA-approved oral XPO1 inhibitor. In May 2018, Karyopharm granted Antengene the rights to the drug in Greater China, South Korea, and ASEAN countries. The drug received conditional approval in China in November 2021, following its approval in South Korea in July of that year. It is used in combination with dexamethasone for the treatment of R/R MM in patients previously treated with at least four therapies and as a monotherapy for recurrent and refractory diffuse large B-cell lymphoma in patients previously treated with at least second-line treatment. Xpovio is already covered by reimbursement drug lists in mainland China, Australia, and Singapore.- Flcube.com
